T-group (topology)
207.1.1 Leucine-rich repeats
Ligands and drugs
13,817
Member domains
1,345
with ligand contacts (≤ 4 Å)
9.7% of members
1,142
with DrugDomain annotations
8.3% of members
1,027
with a DrugBank compound
7.4% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 207.1.1 belongs to X-group 207 Single-stranded right-handed beta-helix, which binds 6.1 ligand superclasses per 20 proteins, narrower than 73% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00141 | NAG | N-Acetylglucosamine | 814 |
| DB02745 | URI | Uridine | 23 |
| DB06530 | RX8 | Resiquimod | 16 |
| DB14981 | IHP | Phytic acid | 9 |
| DB12010 | — | Fostamatinib | 7 |
| DB00724 | 6T0 | Imiquimod | 6 |
| DB02857 | GMP | Guanosine | 6 |
| DB08231 | MYR | Myristic acid | 6 |
| DB15035 | — | — | 6 |
| DB02082 | GNP | Phosphoaminophosphonic acid guanylate ester | 4 |
| DB04315 | GDP | Guanosine-5'-Diphosphate | 4 |
| DB05475 | — | — | 4 |
| DB05944 | — | — | 4 |
| DB06021 | — | — | 4 |
| DB08916 | — | Afatinib | 4 |
| DB09130 | — | — | 4 |
| DB11652 | — | — | 4 |
| DB12267 | — | Brigatinib | 4 |
| DB12687 | 9JR | Vesatolimod | 4 |
| DB16501 | QLH | Enpatoran | 4 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| NAG | 2-acetamido-2-deoxy-beta-D-glucopyranose | 973 |
| CL | CHLORIDE ION | 72 |
| MGmetal | MAGNESIUM ION | 33 |
| IHP | INOSITOL HEXAKISPHOSPHATE | 27 |
| NAmetal | SODIUM ION | 26 |
| ZNmetal | ZINC ION | 26 |
| URI | URIDINE | 25 |
| CAmetal | CALCIUM ION | 23 |
| IDQ | 1-[[4-(aminomethyl)phenyl]methyl]-2-butyl-imidazo[4,5-c]quinolin-4-amine | 21 |
| RX8 | 1-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol | 17 |
| OGK | (1S,2S)-2-ethyl-1-({[(3aS,4S,6R,7aS)-6-ethyl-1-oxooctahydro-1H-inden-4-yl]carbonyl}amino)cyclopropanecarboxylic acid | 16 |
| UCG | 3'-O-[(R)-{[(2R,3aR,4R,6R,6aR)-6-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-2-hydroxy-2-oxidotetrahydrofuro[3,4-d][1,3,2]dioxaphosphol-4-yl]methoxy}(hydroxy)phosphoryl]uridine 5'-(dihydrogen phosphate) | 16 |
| BLD | Brassinolide | 15 |
| 8GI | 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(2-oxidanylpropan-2-yl)furan-2-yl]sulfonyl-urea | 10 |
| GP4 | 2-amino-2-deoxy-4-O-phosphono-alpha-D-glucopyranose | 10 |
| NImetal | NICKEL (II) ION | 10 |
| LP4 | 2-deoxy-3-O-[(3R)-3-hydroxytetradecanoyl]-2-{[(3R)-3-hydroxytetradecanoyl]amino}-4-O-phosphono-beta-D-glucopyranose | 9 |
| 06S | O-[(2R,3S,4R,5R)-5-(2-amino-6-oxo-3,6-dihydro-9H-purin-9-yl)-2-({[(S)-({(2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-hydroxy-2-[(thiophosphonooxy)methyl]tetrahydrofuran-3-yl}oxy)(sulfanyl)phosphoryl]oxy}methyl)-4-hydroxytetrahydrofuran-3-yl] dihydrogen (S)-phosphorothioate | 8 |
| 7JA | N-({(1R,2S)-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl}acetyl)-L-isoleucine | 8 |
| 9K9 | 2-amino-9-[(2S,3aR,4R,6R,6aR)-2-hydroxy-6-(hydroxymethyl)-2-oxotetrahydro-2H-2lambda~5~-furo[3,4-d][1,3,2]dioxaphosphol-4-yl]-3,9-dihydro-6H-purin-6-one | 8 |